Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 08 Mar 2023
Following a major outbreak involving the use of tear drops in 13 US states, experts are offering advice on how to protect dry eyes.
Read Full NewsPreschool-aged children exposed to screens for extended daily periods face elevated prevalence of sleep disturbances.
Treatment rates for US adults with psychiatric disorders are modestly higher than in previous decades, but only a third receive minimally adequate care, new research shows.
An Australian-designed smartphone app uses personalized cognitive bias modification to help users reduce or avoid alcohol consumption.
In patients with cancer receiving immune checkpoint inhibitor therapy, osteoarthritis is linked to the risk for inflammatory arthritis immune-related adverse events.
Researchers evaluate the impact of allogeneic stem cell transplantation in chronic myelomonocytic leukemia across BLAST and BLAST-Mol clinical risk models.
1.
Oncology Care Model’s Net Losses Well Exceed Savings
2.
Atezolizumab + Cabozantinib Postpones mCRPC Progression.
3.
Immunotherapy in Head and Neck Cancer After Failure of Definitive Therapy.
4.
Stem Cell Selection Unneeded for SSc Transplant Therapy?
5.
Cancer diagnosis does not spur improvements to survivors' diets or eating habits
1.
AI on the Front Lines: Revolutionizing Breast Cancer Detection with Artificial Intelligence
2.
Patient Management for Bone Marrow Functional Recovery Pathways
3.
Dexamethasone and Life Expectancy After Pediatric Stem Cell Transplant
4.
Immune Escape Landscapes in Solid Tumors
5.
AI-Powered Strategies for Precision and Improved Outcomes in Esophageal Cancer, a Global Health Crisis
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
1.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
2.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part V
3.
Targeting Oncologic Drivers with Dacomitinib: A New Approach to Lung Cancer Treatment
4.
Thromboprophylaxis In Medical Settings
5.
Navigating the Brain Barrier: The CNS Challenge in ALK+ NSCLC
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge